Harmanci O, Bayraktar Y. How can portal vein cavernous transformation cause chronic incomplete biliary obstruction? World J Gastroenterol 2012; 18(26): 3375-3378 [PMID: 22807606 DOI: 10.3748/wjg.v18.i26.3375]
Corresponding Author of This Article
Dr. Ozgur Harmanci, MD, Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey. firstname.lastname@example.org
Article-Type of This Article
Guidelines For Clinical Practice
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
How can portal vein cavernous transformation cause chronic incomplete biliary obstruction?
Ozgur Harmanci, Yusuf Bayraktar
Ozgur Harmanci, Yusuf Bayraktar, Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey
ORCID number: $[AuthorORCIDs]
Author contributions: Harmanci O and Bayraktar Y contributed equally to this paper.
Correspondence to: Dr. Ozgur Harmanci, MD, Department of Medicine, Division of Gastroenterology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey. email@example.com
Telephone: +90-312-3051714 Fax: +90-312-3051490
Received: November 2, 2011 Revised: February 27, 2012 Accepted: March 19, 2012 Published online: July 14, 2012
Biliary disease in the setting of non-cirrhotic portal vein thrombosis (and similarly in portal vein cavernous transformation) can become a serious problem during the evolution of disease. This is mostly due to portal biliary ductopathy. There are several mechanisms that play a role in the development of portal biliary ductopathy, such as induction of fibrosis in the biliary tract (due to direct action of dilated peribiliary collaterals and/or recurrent cholangitis), loss of biliary motility, chronic cholestasis (due to fibrosis or choledocholithiasis) and increased formation of cholelithiasis (due to various factors). The management of cholelithiasis in cases with portal vein cavernous transformation merits special attention. Because of a heterogeneous clinical presentation and concomitant pathophysiological changes that take place in biliary anatomy, diagnosis and therapy can become very complicated. Due to increased incidence and complications of cholelithiasis, standard treatment modalities like sphincterotomy or balloon sweeping of bile ducts can cause serious problems. Cholangitis, biliary strictures and hemobilia are the most common complications that occur during management of these patients. In this review, we specifically discuss important issues about bile stones related to bile duct obstruction in non-cirrhotic portal vein thrombosis and present evidence in the current literature.
The thrombosis occurring secondary to various causes results in acute and generally asymptomatic thrombosis in an extra-hepatic portion of portal vein transformation (PVT). Eventually, portal vein cavernomatous transformation (PVCT) forms as a compensatory reaction 3 wk to 3 mo after the initial event at the hilum of the liver. However, this salvage also results in inevitable anatomical or functional changes at surrounding structures including the biliary tree, gallbladder and pancreas[1-4]. These changes are secondary to perfusion changes, neovascularization, fibrosis reaction or compression of ducts by newly formed but highly perfused vessels.
Recent terminology uses the term “portal biliopathy” to denote overall anatomical, morphological and functional changes in the biliary tree. The manufactured term “biliopathy” originates from a combination of the Latin word “bilis” (meaning bile) and the Greek word “pathos” (meaning disease) suggesting a disease of liquid bile or its constituents. However, current knowledge lacks compelling evidence of formation of diseased bile in patients with PVCT. Therefore in this review, the term “portal ductopathy” (PD) will be used instead of portal biliopathy as suggested by our group previously.
The changes that take place in the biliary ducts during the course of PVCT can be summarized as strictures, dilatations and varicose veins located at the ductular walls and gallbladder. In the long term, these changes result in biliary stasis, jaundice, cholangitis and cholelithiasis adding more to morbidity and even resulting in mortality (Figures 1 and 2). The superimposition of cholelithiasis observed in the setting of PD is very important since these patients are prone to secondary biliary cirrhosis, a complication observed in 4% of patients. The clinical problem of cholelithiasis observed in chronic, non-cirrhotic PVCT patients is an under-mentioned topic and forms the basis of this compact review. Other clinical problems such as cirrhotic patients, biliary strictures or surgical management related to PD are beyond the scope of this paper.
Figure 1 Liver ultrasound image showing stone (white arrow) and portal vein cavernomatous transformation (black arrow) in gallbladder.
Figure 2 “Portal double ductopathy” sign with stones.
Endoscopic retrograde cholangiopancreatography image of a patient with chronic portal vein cavernomatous transformation showing irregular pancreatic duct and biliary ducts (black arrows). Main bile duct shows local stricture and dilations with cholelithiasis (white arrow).
PATHOGENESIS OF CHOLELITHIASIS IN PORTAL VEIN CAVERNOMATOUS TRANSFORMATION
Theoretically, cholelithiasis in the setting of PD and PVCT may be secondary to chronic cholestasis, changes in the constituents of bile or other factors such as reduced portal flow and associated liver atrophy.
Cholestasis and gallbladder functions
Cholestasis and related clinical findings such as jaundice, pruritus and cholangitis are the most common presenting symptoms in the setting of symptomatic PD and occurs in 5%-30% of all patients[8,9]. Chronic biliary stasis (due to compression in the biliary outflow and loss of bile duct contractility due to either fibrosis or ischemia) may eventually result in stones formed de novo located in biliary ducts and/or gallbladder. The evidence for the proof of this hypothesis is obtained from clinical studies which generally observed pigment stones, located just proximal to the site of ductular stenosis without associated stones in the gallbladder[10,11]. The reduced contractile function of the gallbladder may also contribute to development of stones due to the presence of varicose veins in the gallbladder wall, but in one study the contractile function of gallbladder has been found to be unchanged. Thus, cholestasis is believed to develop at later stages of PD secondary to fibrosis and compression of newly formed vessels, which are a major factors for development of stones. Once formed, stones further contribute to cholestasis and stricture formation by initiating recurrent cholangitis attacks.
Change in the constituents of bile
There is a small amount of evidence in the literature to indicate a change in the composition of bile resulting in a tendency for development of cholelithiasis. Previous studies investigating the contribution of reduced portal flow for development of cholelithiasis found that there is an increased tendency towards formation of stones after selective portal vein ligation in dogs. Also, temporary interruption of portal flow leads to decreased bile acid synthesis and biliary flow. There is no human study in the literature to indicate definitive changes in biliary composition take place during PVCT. Hypothetically speaking, presence of abnormal portal inflow might contribute to formation of lithogenic bile either by causing hypersplenism and increased pigment load in bile or abnormal enterohepatic circulation of bile acids due to portal hypertension.
FREQUENCY AND CLINICAL FINDINGS OF CHOLELITHIASIS IN PORTAL VEIN CAVERNOMATOUS TRANSFORMATION
The findings obtained from key studies concerning cholelithiasis observed in PVT-PVCT (in adult and pediatric populations) are summarized in Table 1. The frequency of cholelithiasis is highly variable (0%-84%). Probably, this variability is secondary to the problem of potential bias in patient selection criteria. Most of the studies only included patients with symptoms in a retrospective design or included patients with chronic liver disease-cirrhosis or with mass-occupying lesions. In most of these studies, investigation methods [endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography or ultrasound] were not uniform so it was not possible to make a definitive conclusion about incidence and prevalence of stones. The choice of investigation method has been found to have a clear impact on the results of anatomical location of cholelithiasis found in the biliary system. Therefore, current literature lacks prospective and well-designed studies to reveal the exact prevalence and incidence of cholelithiasis in a group of well selected PVCT patients irrespective of presence of symptoms.
Table 1 Cholelithiasis and important findings from selected studies.
21 patients selected out of 35, selection criteria not mentioned
PVT: Portal vein transformation; ERCP: Endoscopic retrograde cholangiopancreatography; MRCP: Magnetic resonance cholangiopancreatography; PD: Portal ductopathy; CBD: Common bile duct; GB: Gallbladder; PVCT: Portal vein cavernomatous transformation.
The clinical findings related to cholelithiasis in PVCT patients are not different from patients who do not have PVCT, but it is evident that it results in a high frequency of PD symptoms. Cholelithiasis is found more commonly in patients with biliary findings such as jaundice, biliary colic, cholangitis and elevated liver enzymes compared with asymptomatic patients[7,15].
The management of stones in patients with PVCT merits special attention since concomitant changes in the biliary system may jeopardize standard therapeutic procedures. The collaterals of Petren and Saint around major bile ducts enlarge in response to PVCT and they form the basis of collateral vessel compression to major bile ducts in PD[6,7]. Also, secondary to ischemic injury and development of fibrous tissue in the major biliary ducts, biliary interventions should be performed with caution. Since these varicose collaterals and fibrous strictures may result in detrimental complications like hemobilia or recurrent cholangitis, clinicians should follow special management strategies being aware of these potential risks. Otherwise, therapeutic strategies for cholelithiasis in PD are not different from other patient groups.
In previous studies focusing on treatment of PD, the major concern and attention was given to the problem of biliary strictures. The treatment of strictures and associated cholestasis is important since resolving these factors also reduces the risk of formation or recurrence of cholelithiasis. Biliary stricture and associated jaundice can be managed by medical treatment with ursodeoxycholic acid[11,16] or by interventions like biliary stenting[16-18], balloon dilatation or portosystemic shunting. If present, cholelithiasis should first be managed by evaluation of varicose veins around the common bile duct, either by magnetic resonance angiography or endoscopic ultrasonography. After elimination of varicose veins, standard sphincterotomy and balloon trawl for extraction of common bile duct stones and/or sludge should be employed. The presence of any collateral varicose vein is very important since inadvertent interventions like basket removal of stones or biliary stenting might result in bothersome hemobilia[21-25] requiring massive transfusions, injection sclerotherapy, terlipressin or urgent portosystemic shunting . In our personal experience, we propose that papillotomy should be performed at earlier stages of disease as a prophylactic measure to make future ERCP procedures safer and easier. If not performed earlier, varices and fibrosis in the distal main bile duct can preclude or complicate safe papillotomy.
In conclusion, cholelithiasis and choledocholithiasis in the setting of PVCT and PD is a specific problem that needs special attention. Stones can become very problematic and interventions may result in severe hemobilia. Stone extraction by balloon or basket trawl can be gruelling due to strictures and fibrosis in biliary system. If present, biliary strictures and severe vascular compression should be treated by medical or interventional treatments in order to facilitate stone extraction and reduce recurrence. Further well designed prospective studies are required to clearly understand the exact natural history of cholelithiasis in PVCT patients.
Peer reviewer: Hongjoo Kim, Professor, Sungkyunkwan Uni-versity Kangbuk Samsung Hospital, 108, Pyung-Dong, Jongro-Ku, Seoul 110-746, South Korea
S- Editor Gou SX L- Editor O’Neill M E- Editor Li JY
Bayraktar Y, Balkanci F, Kayhan B, Ozenç A, Arslan S, Telatar H. Bile duct varices or "pseudo-cholangiocarcinoma sign" in portal hypertension due to cavernous transformation of the portal vein.Am J Gastroenterol. 1992;87:1801-1806.
[PubMed] [DOI][Cited in This Article: ]
Bayraktar Y, Balkanci F, Ozenc A, Arslan S, Koseoglu T, Ozdemir A, Uzunalimoglu B, Telatar H, Gurakar A, Van Thiel DH. The "pseudo-cholangiocarcinoma sign" in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels.Am J Gastroenterol. 1995;90:2015-2019.
[PubMed] [DOI][Cited in This Article: ]
Bayraktar Y, Harmanci O, Ersoy O, Aydinli M, Balkanci F. "Portal double ductopathy sign" in patients with portal vein cavernous transformation.Hepatogastroenterology. 2008;55:1193-1200.
[PubMed] [DOI][Cited in This Article: ]
Adachi Y, Kamisako T, Yamamoto T. The effects of temporary occlusion of the superior mesenteric vein or splenic vein on biliary bilirubin and bile acid excretion in rats.J Lab Clin Med. 1991;118:261-268.
[PubMed] [DOI][Cited in This Article: ]